Dublin, July 03, 2026 (GLOBE NEWSWIRE) -- The "Medullary Thyroid Cancer - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.
The "Medullary Thyroid Cancer - Pipeline Insight, 2026" report offers a detailed exploration of the medullary thyroid cancer (MTC) pipeline landscape, with insights into more than eight companies and over ten pipeline drugs. This report provides a thorough overview of MTC, including the clinical and nonclinical stage products and therapeutic assessments based on product type, stage, route of administration, and molecule type, while highlighting inactive pipeline products.
Overview Medullary thyroid cancer (MTC) originates from the parafollicular C cells of the thyroid gland, responsible for producing calcitonin. Although MTC accounts for only a small percentage of all thyroid cancers, it is clinically significant due to its aggressive behavior and early metastatic tendency. It is driven by activating mutations in the RET proto-oncogene leading to uncontrolled growth and transformation to cancer.
Genetic alterations in the RET proto-oncogene, including germline RET mutations associated with MEN2 syndromes and somatic RET or RAS mutations, are primary contributors to MTC's development. Diagnostic approaches involve clinical evaluation, biochemical testing, imaging, pathology, and genetic testing for RET mutations. Surgical removal of the thyroid, often with lymph node dissection, is the primary treatment method, as MTC is resistant to radioactive iodine and TSH suppression therapy.
Comprehensive Insights The report outlays in-depth commercial and clinical assessments of pipeline products under development. It details drug mechanisms, clinical studies, NDA approvals, product development activities, collaborations, licensing, mergers & acquisitions, funding, designations, and other product-related details.
Current Developments Companies and academics are exploring challenges and opportunities that could shape MTC R&D, focusing on innovative approaches in the latest drugs development. The report encapsulates this through detailed analysis across various phases including phase II, I, preclinical, and discovery stages, involving insights on clinical trials, pharmacological actions, agreements, and recent news.
Emerging Drugs Notable drugs include Regorafenib by Bayer Healthcare, a kinase inhibitor blocking tumor growth and angiogenesis, currently in Phase II, and APS03118 from Applied Pharmaceutical Science, a selective RET inhibitor in Phase I, demonstrating remarkable antitumor activity.
Detailed Therapeutic Assessment The report assesses drugs by stages of development: late-stage (Phase III), mid-stage (Phase II), early-stage (Phase I), and pre-clinical & discovery candidates. Route of administration coverage includes intra-articular, intraocular, intrathecal, intravenous, ophthalmic, oral, parenteral, subcutaneous, topical, and transdermal. Molecule types involve oligonucleotide, peptide, and small molecule, and product types include mono, combination, and mono/combination therapies.
Key Players and Development Activities Insights on collaborations, acquisitions, licensing, and pipeline development activities provide a comprehensive view of the therapeutic candidates and key players advancing MTC research. Key players in MTC drug development include Bayer Healthcare and Applied Pharmaceutical Science, with products like Regorafenib and APS0311.
Research and Development Inquiries Key questions explore the number of developers, emerging drugs in various development stages, key collaborations and licensing activities, trends in overcoming existing therapy limitations, ongoing clinical studies, and designations granted to emerging drugs.
Key Topics Covered:
Introduction
Executive Summary
Medullary Thyroid Cancer: Overview
- Introduction
- Pathophysiology
- Causes
- Diagnosis
- Treatment
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Medullary Thyroid Cancer- Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Regorafenib: Bayer Healthcare
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
APS03118: Applied Pharmaceutical Science
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Drug name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Medullary Thyroid Cancer Key Companies
Medullary Thyroid Cancer Key Products
Medullary Thyroid Cancer - Unmet Needs
Medullary Thyroid Cancer - Market Drivers and Barriers
Medullary Thyroid Cancer - Future Perspectives and Conclusion
Medullary Thyroid Cancer Analyst Views
Medullary Thyroid Cancer Key Companies
Appendix
List of Tables
Table 1 Total Products for Medullary Thyroid Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Medullary Thyroid Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer Healthcare
- Applied Pharmaceutical Science
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/a39ku7
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
